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Abstract
Introduction Estrogen and insulin-like growth factor-1 (IGF-1)
play important roles in mammary gland development and breast
cancer. SirT1 is a highly conserved protein deacetylase that can
regulate the insulin/IGF-1 signaling in lower organisms, as well
as a growing number of transcription factors, including NF-κB,
in mammalian cells. Whether SirT1 regulates the IGF-1
signaling for mammary gland development and function,
however, is not clear. In the present study, this role of SirT1 was
examined by studying SirT1-deficient mice.
Methods SirT1-deficient (SirT1ko/ko) mice were generated by
crossing a new strain of mice harboring a conditional targeted
mutation in the SirT1 gene (SirT1co/co) with CMV-Cre transgenic
mice. Whole mount and histology analyses,
immunofluorescence staining, immunohistochemistry, and
western blotting were used to characterize mammary gland
development in virgin and pregnant mice. The effect of
exogenous estrogen was also examined by subcutaneous
implantation of a slow-releasing pellet in the subscapular region.
Results Both male and female SirT1ko/ko mice can be fertile
despite the growth retardation phenotype. Virgin SirT1ko/ko mice
displayed impeded ductal morphogenesis, whereas pregnant
SirT1ko/ko mice manifested lactation failure due to an
underdeveloped lobuloalveolar network. Estrogen implantation
was sufficient to rescue ductal morphogenesis. Exogenous
estrogen reversed the increased basal level of IGF-1 binding
protein-1 expression in SirT1ko/ko mammary tissues, but not that
of IκBα expression, suggesting that increased levels of estrogen
enhanced the production of local IGF-1 and rescued ductal
morphogenesis. Additionally, TNFα treatment enhanced the
level of the newly synthesized IκBα in SirT1ko/ko cells. SirT1
deficiency therefore affects the cellular response to multiple
extrinsic signals.
Conclusion SirT1 modulates the IGF-1 signaling critical for
both growth regulation and mammary gland development in
mice. SirT1 deficiency deregulates the expression of IGF-1
binding protein-1 and attenuates the effect of IGF-1 signals,
including estrogen-stimulated local IGF-1 signaling for the onset
of ductal morphogenesis. These findings suggest that the
enzymatic activity of SirT1 may influence both normal growth
and malignant growth of mammary epithelial cells.
Introduction
Mammalian SirT1 belongs to a family of nicotinamide adenine
dinucleotide-dependent histone deacetylases [1,2]. SirT1 is
most closely related to yeast Sir2, the founding member of the
evolutionarily conserved Sir2 family. Yeast Sir2 is required for
silencing transcription at the telomeric region and mating type
loci, and for suppression of ribosomal DNA recombination
[3,4]. The expression of an extra copy of Sir2 in either yeastPage 1 of 12
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significantly extend the lifespan [5,6]. Inactivation of Sir2
enhances stress resistance and extends chronological
lifespan of nondividing yeast cells, which is opposite to the
requirement for Sir2 function in the reproductive lifespan [7].
Whether SirT1 regulates the reproductive lifespan and/or the
chronological lifespan in mammals remains unknown.
Sir2 is an integral part of an evolutionarily conserved insulin/
insulin-like growth factor-1 (IGF-1) signaling (IIS) system in
worms (Caenorhabditis elegans), fruit flies (Drosophila), mice,
and humans [8,9]. The IIS system includes membrane-bound
receptors, cytoplasmic kinases, and nuclear transcription fac-
tors. To maintain the proper expression of the effector genes
for the IIS system, these conserved components form a
sophisticated regulatory system, which centers on a family of
forkhead transcription factors (forkhead box 'other' proteins
(FoxOs)), and operates on two levels. On one level, SirT1-
mediated protein deacetylation attenuates the transcriptional
activity of nuclear FoxO transcription factors [10-12]. On the
second level, the FoxO transcription factors can be seques-
tered within the cytoplasm when phosphorylated by activated
Akt kinases in response to insulin and IGF-1 signals [13]. Con-
ceivably, the IIS system senses the levels of insulin and IGF-1
and negatively regulates the expression of the effector genes.
The IIS system is responsible for food storage, stress toler-
ance, and longevity in lower organisms, such as C. elegans
[8,9,14]. In more advanced species, steroid hormones evolved
to regulate the IIS system [15]. In mice and humans, the IGF-
1 signaling of the IIS system mediates local effects for growth
and hormonal regulation for multiple tissues, including mam-
mary glands [16,17].
Mammalian SirT1 has evolved to modify the activity of a grow-
ing number of transcription factors, including p53, NF-κB, and
PGC-1α, suggesting that SirT1 functions in a wide range of
cellular responses to stress, inflammation, and nutrients [18-
21]. SirT1-deficient mice display characteristic phenotypes of
perinatal death and growth retardation as well as other diverse
phenotypes, such as eye defects, with varying severity
[22,23]. The underlying causal mechanism for these pheno-
types, however, remains unknown. We recently generated
SirT1-deficient (SirT1ko/ko) mice and found that both male and
female SirT1ko/ko mice can be fertile, which is in contrast to the
sterile phenotypes observed in one strain of SirT1-deficient
mice [22]. This led to our study of the link between SirT1 and
IGF-1 signaling using the mammary gland as a model organ.
The mammary gland is a unique organ because it develops
after birth and undergoes dynamic changes throughout the
reproductive lifespan of a female. At the onset of puberty, ovar-
ian estrogen stimulates ductal morphogenesis during which
mammary epithelial progenitor cells differentiate and prolifer-
ate while interacting with adipocytes and stromal cells within
mammary fat pad [17,24,25]. Ovarian estrogen, in synergy
with pituitary growth hormone (GH), stimulates stromal cells to
produce local IGF-1. The local IGF-1, but not liver-produced
systemic IGF-1, provides a paracrine signal for commencing
ductal morphogenesis [26]. Mice lacking GH, estrogen, IGF-
1, GH receptor, or estrogen receptor alpha (ERα) fail to
undergo postnatal ductal morphogenesis [17,24-31], indicat-
ing that both steroid hormones and IGF-1 are on the common
pathway for a critical developmental checkpoint. Once the
arborated ductal network is established, cycles of differentia-
tion, proliferation, and death of secretory alveolar epithelium
repeat with each pregnancy [17,24,25].
In the present article we report the finding and characterization
of impeded ductal morphogenesis in virgin SirT1ko/ko mice and
lactation failure in SirT1ko/ko mothers. The characterization of
these phenotypes has identified a SirT1-dependent regulatory
mechanism by which SirT1 modulates the effectiveness of the
estrogen–IGF-1 signaling for mammary gland development.
The estrogen–IGF-1 signaling is defined as the ovarian estro-
gen-regulated, stromal cell-produced local IGF-1 signal for
stimulating mammary epithelial cells.
Materials and methods
Mice
A previously described SirT1 targeting construct, KOII [23],
was used to generate mice harboring a conditional targeted
mutation in the SirT1 gene (SirT1co/co mice) (see Additional file
1). The breeding of SirT1co/co mice and CMV-Cre transgenic
mice results in mice harboring a germline-transmitted deletion
of exon 4 of the SirT1 gene (SirT1+/ko mice). Both SirT1co/co
mice and SirT1+/co mice were used to establish breeding col-
onies for generating SirT1co/co and SirT1ko/ko mice, respec-
tively. Both SirT1co/co mice and SirT1ko/ko mice were in a mixed
129SvJ/C57B6 background. Mice were housed in a special-
pathogen-free facility and all procedures were approved by the
University of Washington Animal Care and Use Committee. A
PCR-based genotyping method was established to identify
the wild-type, co, and ko loci of the SirT1 gene using three
primers: 5' co primer, 5'-GGTTGACTTAGGTCTTGTCTG; 5'
ko primer, 5'-AGGCGGATTTCTGAGTTCGA; 3' primer, 5'-
CGTCCCTTGTAATGTTTCCC. Murine embryonic fibroblasts
(MEFs) were isolated from the embryos between embryonic
day 12.5 and embryonic day 14.5. The body weight was meas-
ured once a week.
Serum insulin-like growth factor-1
A commercial radioimmunoassay (ALPCO Inc., Windham, NH,
USA) was used. Samples (300 μl) were prepared via an alco-
hol extraction followed by a 2-day disequilibrium incubation at
4°C. Samples were measured in duplicate and data were cal-
culated as the samples were counted. Six standards ranging
from 10 to 500 ng/ml were used to generate the standard
curve. The lower limit of detection was 10 ng.Page 2 of 12
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To determine the sensitivity of embryonic stem cells after ion-
izing radiation or hydrogen peroxide treatment, 300 embryonic
stem cells were seeded onto a 10-cm plate for 24 hours. The
plates were either exposed to a 137Cs source at indicated
doses or were treated with embryonic stem media containing
hydrogen peroxide at indicated concentrations for 30 minutes.
Seven days after irradiation or hydrogen peroxide treatment,
the embryonic stem colonies stained with crystal violet were
counted.
Estrogen implantation
Estrogen pellets in the form of 17β-estradiol, at 0.1 mg, and
the 21-day releasing time were obtained from Innovative
Research (Sarasota, FL, USA). One pelletwas subcutaneously
implanted in the subscapular region ofindividual female mice
using a sterilizedmetal trochar (Innovative Research).
Whole mount analysis
The inguinoabdominal mammary fat pads were spread on
microscope slides, fixed in Carnoy's fixative overnight,
hydrated and stained with carmine alum stain (Sigma, St.
Louis, MO, USA) overnight, and were then dehydrated, treated
with xylene to remove fat, and mounted with Secure Mount
(Fisher Scientific, Pittsburgh, PA, USA) and cover slips.
Histological, immunohistochemical, and 
immunofluorescence analyses
The mice were given a single dose of bromodeoxyurdine
(BrdU) at 100 g/kg body weight via intraperitoneal injection 2
hours before euthanasia. The mammary fat pads, as well as
other tissues, were collected and fixed in 10% formalin solu-
tion (Fisher Scientific). Paraffin-embedded sections were pre-
pared at 4 μm thickness followed by standard H & E staining
for histological analysis and by immunohistochemical staining
for BrdU-labeled cells (Sigma) and apoptotic cells (Promega,
Madison, WI, USA). To detect the presence of mouse milk pro-
teins, a rabbit anti-mouse milk specific protein antibody (Nor-
dic Immunology, Tillburg, The Netherlands) was used for
immunofluorescent staining, followed by Texas Red anti-rabbit
secondary antibody (Molecular Probes) and DAPI staining for
nuclei (Molecular Probe, Eugene, OR, USA). Microscopic
analyses of all histological findings were carried out on an
AxioVert 200M microscope with AxioVision 4.5 software (Carl
Zeiss, München-Hallbergmoos, Germany).
Protein analysis
Protein extracts were prepared from mammary tissues as well
as from MEFs. The following primary antibodies were used:
anti-SirT1 (Upstate Biotechology, Lake Placid, NY, USA), anti-
IGF-1 binding protein-1 (IGFBP-1) (R&D Systems, Minneapo-
lis, MN, USA), and anti-actin and anti-IκBα (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The corresponding
secondary antibodies were horseradish peroxidase-conju-
gated anti-rabbit (Pierce, Rockford, IL, USA), anti-rat, and anti-
goat (Santa Cruz Biotechnology).
Results
Growth retardation in SirT1ko/ko mice
The conditional targeted SirT1 mutant mice (SirT1co/co mice)
carry an insertion mutation of the neomycin-resistant gene and
lox sequences in the SirT1 gene flanking exon 4 that encodes
a conserved Sir2 motif (Figure 1a). The mutation does not
affect the expression of SirT1 in SirT1co/co mice (Figure 1b). As
expected, SirT1co/co mice are phenotypically indistinguishable
from wild-type mice. To convert the SirT1 co allele into the
SirT1 ko allele, SirT1co/co mice were crossed with CMV-Cre
transgenic mice to generate SirT1 heterozygotes carrying the
SirT1+/ko, CMV-Cre+ genotype. The expression of the CMV-
Cre transgene catalyzes the deletion of exon 4 in most line-
ages of cells, including germ cells (Figure 1a). This SirT1 ko
allele should be identical to the previously described Δex4
mutation [23]. SirT1+/ko, Cre+ mice were backcrossed with
wild-type mice to generate the mice harboring a germline-
transmitted deletion mutation (that is, SirT1+/ko mice). The
breeding of SirT1+/ko male mice and SirT1+/ko female mice
resulted in SirT1ko/ko mice. The cells derived from either
SirT1+/ko mice or SirT1ko/ko mice expressed a SirT1 mutant
protein due to the inframe deletion of exon 4 (Figure 1b). This
SirT1 mutant protein may not be functional, however, since
SirT1+/ko mice are phenotypically indistinguishable from wild-
type mice and SirT1Δex4/Δex4 mice were phenotypically identi-
cal to SirT1 null mice [23].
Similar to other strains of SirT1-deficient mice, nearly two-
thirds of SirT1ko/ko newborns die shortly after birth and the
majority of surviving SirT1ko/ko mice manifest growth retarda-
tion (Table 1 and Figure 1c) [22,23]. Growth retardation may
result from a systemic defect in hormonal regulation, DNA dou-
ble-strand break repair, or other causal mechanisms. We
found that SirT1ko/ko mice have reduced levels of serum IGF-1
(Figure 1d). IGF-1 often acts as a local effector for pituitary
GH. The serum level of GH in SirT1ko/ko mice, however,
appeared to be within the normal range (data not shown). On
the other hand, yeast Sir2 and its associated Sir complex, as
well as mouse SirT6, have also been implicated in DNA dou-
ble-strand break repair and the maintenance of chromosome
stability [32-34]. We found that SirT1ko/ko embryonic stem
cells do not have increased sensitivity to either ionizing radia-
tion or hydrogen peroxide treatment when compared with
wild-type cells, or with positive control cells such as Ku70-
deficient or Atm-deficient cells (Figure 1e,f). Both Ku70-defi-
cient mice and Atm-deficient mice display growth retardation
phenotypes [35,36]. The growth retardation phenotype in
SirT1ko/ko mice is therefore probably not due to a defect in
DNA damage repair, but rather results from a deficit in IGF-1
signaling.Page 3 of 12
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Both male and female SirT1ko/ko mice can be fertile, which is in
contrast with the reported sterile phenotype in one strain of
SirT1-deficient mice [22]. When male SirT1ko/ko mice impreg-
nated female SirT1+/ko mice, the number of surviving SirT1ko/ko
offspring was reduced due to the partial perinatal lethal phe-
notype (Table 1). In a reciprocal approach, male SirT1+/ko mice
can also impregnate female SirT1ko/ko mice (Table 1). After
parturition, SirT1ko/ko mothers exhibited normal nursing behav-
ior. The pups did not survive for more than 3 days after birth,
however, unless they were immediately removed and put
under the care of a foster mother. All pups died of dehydration
or starvation as a result of lack of milk in their stomachs.
To determine whether the SirT1ko/ko mothers encountered a
lactation defect, whole mount and histological analyses were
used to characterize the morphological changes in the mam-
mary glands. We found that virgin SirT1ko/ko mice displayed
impeded ductal morphogenesis up to 9 months of age, while
age-matched virgin wild-type mice displayed extensive ductal
elongation and branching (Figure 2a). The absence of ductal
morphogenesis persisted in pregnant SirT1ko/ko mice up to day
13 of pregnancy (Figure 2b). Despite the fact that pregnancy
can induce ductal morphogenesis at the late stage of preg-
nancy, underdeveloped mammary glands in SirT1ko/ko female
mice cause a severe deficit in milk production, as shown by
histological analysis as well as the immunofluorescence anal-
ysis using an anti-milk antibody (Figure 2b,c).
Pregnancy-induced mammary gland development
To characterize the developmental defect leading to lactation
failure, we analyzed the mammary glands of SirT1ko/ko female
mice on lactation day 1. Terminal end buds (TEBs) are club-
shaped transitional structures (see Figure 3a, upper panel). In
Figure 1
Generation and characterization of SirT1co/co and SirT1ko/ko micetion and characterization of SirT1 /co and SirT1ko/ko mice. (a) Mouse SirT1 wild-type allele (SirT1+), conditional targeted allele (SirT1co), 
and knockout allele (SirT1ko). B, BamHI. (b) Western blot analysis of SirT1 expression in wild-type (+/+), conditional targeted (co/co), heterozygote 
(+/ko), and knockout (ko/ko) murine embryonic fibroblasts (MEFs) and mammary tissues (MG). (c) Growth retardation in surviving SirT1ko/ko mice 
(open bar) using sibling mice or age-matched mice of control genotypes (filled bar). (d) The serum levels of insulin-like growth factor-1 (IGF-1) in 
wild-type (+/+), SirT1+/ko (+/ko), and SirT1ko/ko (ko/ko) mice. (e) The survival curves of wild-type (WT), SirT1co/co, SirT1ko/ko, and Ku70-/- embryonic 
stem cells after ionizing radiation. (f) The survival curve of wild-type (WT), SirT1ko/ko, Ku70-/-, and Atm-/- embryonic stem cells after treatment with 
hydrogen peroxide.
Table 1
Perinatal lethality, fertility, and lactation defect in SirT1ko/ko mice
Parents Pups
Male Female Litter Survivorsa +/+ +/ko ko/ko
+/ko +/ko 47 340 101 208 31
ko/ko (n = 3) +/ko 11 55 - 45 10
+/ko ko/ko (n = 5) 8 0 - (13) (13)
More than 10 pairs of SirT1+/ko male mice and SirT1+/ko female mice were used for breeding. Data in parentheses indicate the number of pups of 
this genotype found dead within 3 days after their birth. aTotal number of surviving pups at weaning (postnatal day 21).Page 4 of 12
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Available online http://breast-cancer-research.com/content/9/1/R1wild-type female mice, TEBs form and precede ductal elonga-
tion and branching at the onset of puberty [17,24,25]. When
TEBs/ducts reach the edge of mammary fat pads, TEBs
regress as shown in the virgin mice in Figure 3a (upper panel).
Interestingly, the transitional TEBs can be readily identified in
SirT1ko/ko female mice on lactation day 1, manifesting as either
newly formed TEBs or as TEBs attached to developing ductal
and alveolar structures (Figure 3a, lower panel). Moreover,
SirT1ko/ko mice displayed varying degrees of ductal develop-
ment, ranging from a lack of any ductal structure to a fully
developed ductal network, the latter of which is comparable
with the morphology and cellularity of wild-type mammary tis-
sues on day 13 of pregnancy (Figure 3a). These observations
indicated that pregnancy could rescue impeded ductal mor-
phogenesis in virgin SirT1ko/ko mice.
Normal alveolar morphogenesis takes place under the control
of additional hormones and growth factors during pregnancy
and lactation [17,24,25]. These coordinated efforts are neces-
sary to support a densely saturated lobuloalveolar system for
secreting milk after parturition (see wild-type mice on lactation
day 1 in Figures 2b and 3a). In some SirT1ko/ko mice, the alve-
olar morphogenesis was initiated, as indicated by the pres-
ence of a few secretory alveolar epithelial cells within
scattered alveolar structures sprouted from a well-established
ductal branching network (Figures 2c and 3a, lower panel).
The extent of alveolar morphogenesis in SirT1ko/ko mice was
inadequate, however, as shown by the severe deficit in milk
production when compared with that in wild-type mice (Figure
2c).
Exogenous estrogen-induced ductal morphogenesis
To test whether the increased levels of estrogen in pregnant
mice were sufficient to induce ductal morphogenesis in
SirT1ko/ko mice, a single estrogen pellet was implanted in the
subscapular region of each virgin SirT1ko/ko mouse and the
mammary tissues were analyzed 14 and 21 days after the
implantation. By day 14, wild-type mice displayed ductal side
branching reminiscent of the morphological changes during
early pregnancy (Figure 4a, left panel). In contrast, SirT1ko/ko
mice showed TEBs and ductal elongation, which are the char-
acteristic features of ductal morphogenesis in pubertal wild-
type mice. By day 21, ductal elongation and side branching
were restored in SirT1ko/ko mice and the extent of ductal mor-
phogenesis was indistinguishable between wild-type and
SirT1ko/ko female mice (Figure 4a, right panel). These observa-
tions clearly indicated that exogenous estrogen alone is suffi-
cient to rescue ductal morphogenesis in virgin SirT1ko/ko mice.
Furthermore, the presence of transitional TEBs on day 14 and
of ductal side branching on day 21 suggested that the charac-
teristic features of mammary gland development at puberty
and during early pregnancy could be coupled in response to
increasing levels of estrogen. Increased levels of estrogen,
either during pregnancy or through implantation, were there-
fore sufficient to stimulate the differentiation of epithelial pro-
genitor cells and ductal morphogenesis in virgin SirT1ko/ko
mice.
Concurrent mammary epithelial cell proliferation and 
differentiation
The finding of pregnancy-induced mammary gland develop-
ment prompted us to investigate how mammary epithelial pro-
genitor cells in pregnant SirT1ko/ko mice can differentiate so
rapidly. Both BrdU labeling and the TUNEL (Terminal deoxynu-
cleotidyl transferase mediated dUTP Nick End Labeling) assay
were used to measure the cell proliferation and apoptosis in
the mammary tissues, respectively. We found in SirT1ko/ko
mammary tissues that about one-third of the cells in TEBs
were BrdU-positive as compared with the number of BrdU-
positive cells in the newly differentiated ductal or alveolar epi-
thelial cells (Figure 5a(upper panel), 5b). This BrdU-positive
finding differs from that in wild-type mammary tissues, in which
less than 3% of ductal epithelial cells and about 25% of alve-
Figure 2
Lactation failure in SirT1ko/ko micei  failure in SirT1ko/ko mice. (a) Whole mount analysis of the 
mammary tissues from virgin wild-type (+/+) and SirT1ko/ko mice (ko/
ko). Scale bar = 2 mm. (b) Histological analysis of the mammary tis-
sues harvested from wild-type (+/+) and SirT1ko/ko female mice on 
either day 13 of pregnancy (P13) or lactation day 1 (L1). Scale bars = 
100 μm. (c) Immunofluorescence staining of milk production in the 
mammary tissues from wild-type (+/+) and SirT1ko/ko mice on L1. Red 
and smear stains, mouse milk proteins; blue dots, nuclear staining of 
adipocytes, epithelial cells, and other cells in mammary tissues. Scale 
bars = 100 μm.Page 5 of 12
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ductal epithelial cells in SirT1ko/ko mice formed elongated
ducts and side branches, while pushing TEBs towards the
edge of mammary fat pad (Figure 3a, lower panel). The newly
generated ductal epithelial cells can consequently further dif-
ferentiate into a few observed alveolar cells in which milk pro-
teins were detected (Figure 2c). These observations
suggested that the proliferation and differentiation of epithelial
progenitor cells, which is programmed to take place at differ-
ent times of a female's reproductive life, could be concurrent
at a late stage of pregnancy in SirT1ko/ko mice.
Apoptosis is a part of the self-renewal and remodeling proc-
esses in normal mammary tissues [17,24,25]. Apoptotic
epithelial cells can be readily identified in both ductal and alve-
olar epithelium of SirT1ko/ko mice on lactation day 1 (Figure 5a,
lower panel). The levels of apoptotic cells were significantly
higher than those in wild-type mice on lactation day 1, but
seemed to be closer to that in wild-type mice in mid-pregnancy
(e.g. day 13 of pregnancy) (Figure 5c). The rush of proliferation
and differentiation during pregnancy-rescued ductal develop-
ment in SirT1ko/ko mice manifested multiple features on
lactation day 1 that could reassemble some characteristic fea-
tures of wild-type mice in mid-pregnancy. Successive preg-
nancies, however, failed to improve the survival rate of either
SirT1+/ko pups or SirT1ko/ko pups (three or four pregnancies in
3 months for each of three SirT1ko/ko females tested), indicat-
ing that the lactation defect persisted. A SirT1 deficiency
therefore affected ductal morphogenesis in virgin mice, and
lobuloalveolar proliferation in parous mice.
Deregulated negative feedback signals
The characterization of lactation failure has revealed two
developmental defects in SirT1ko/ko female mice. The impeded
ductal morphogenesis in virgin SirT1ko/ko mice bore some
resemblance to the defective ductal morphogenesis seen in
Figure 3
Pregnancy-induced ductal morphogenesisncy-induced ductal morphog nesis. (a) Whole mount analysis of mammary gland development. Upper panel: wild-type (+/+) mice show 
terminal end buds (TEBs) at the onset of puberty, elongated ducts (virgin mice), site branching during pregnancy (P13), and lobuloalveolar struc-
tures for milk production on lactation day 1 (L1). Lower panel: virgin SirT1ko/ko (ko/ko) mice show impeded ductal morphogenesis. Pregnancy-
induced ductal morphogenesis manifests transitional TEBs, ductal elongation, and side branching with variety in three SirT1ko/ko mice on L1. All scale 
bars = 200 μm. (b) Western blot analysis of both insulin-like growth factor-1 binding protein-1 (IGFBP-1) and IκBα in mammary tissues of male 
mice, virgin mice, and L1 female mice of wild type (+/+) and SirT1ko/ko (ko/ko). Actin is used as a loading control. Lower panel scores the estimated 
density of indicated lineages of cells in the protein extracts, which are based on the morphological analyses in (a).Page 6 of 12
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ing mutations in the corresponding receptors, such as the GH
receptor and ERα [17,24-31]. These previous studies have
established the notion that GH and estrogen synergistically
stimulate ductal morphogenesis, which is mediated by stromal
cell-produced local IGF-1 in mammary tissues. Impeded duc-
tal morphogenesis in virgin SirT1ko/ko mice is therefore proba-
bly due to a deficit in IGF-1 signaling.
In addition to this early defect, pregnancy-induced mammary
gland development in SirT1ko/ko mice appeared to be arrested
at the beginning of lobuloalveolar development, which is remi-
niscent of the phenotype in mice lacking IκB kinase alpha
(IKKα) activity for NF-κB activation [37]. IKKα-deficient mice
exhibit normal ductal morphogenesis at the onset of puberty
and exhibit normal ductal side branching during early preg-
nancy. Owing to the absence of NF-κB-dependent cyclin D1
expression, however, IKKα-deficient mice display defective
alveolar epithelial cell proliferation and fail to lactate [37].
While SirT1 negatively regulates the transcription activity of
FoxOs and NF-κB in mammalian cells [10,11,20], SirT1ko/ko
mice displayed the loss-of-function phenotypes. We hypothe-
sized that SirT1 deficiency deregulates the expression of neg-
ative feedback signals and thereby desensitizes the cells to
various types of stimulation. Indeed, among the many FoxOs
and NF-κB-regulated genes, IGFBP-1 and IκBα encode neg-
ative feedback signals for IGF-1 signaling and NF-κB activa-
tion, respectively. We found that the basal levels of both
IGFBP-1 and IκBα were increased in adipose tissues from vir-
gin SirT1ko/ko mice and in ductal epithelial cells from SirT1ko/ko
mice on lactation day 1 (Figure 3b). Meanwhile, the expression
pattern of IGFBP-1 and IκBα in wild-type mammary tissues,
shown in Figure 3b, was in agreement with the findings of oth-
ers [16,38,39]. Namely, the expression of IGFBP-1 was down-
regulated during pregnancy, whereas NF-κB activity was
increased at a late stage of pregnancy. The loss of SirT1 there-
fore increased the basal level of both IGFBP-1 and IκBα in
multilineages of cells, and potentially increased thresholds for
activating SirT1-modulated signaling pathways.
SirT1 deficiency did not affect the ability of mammary epithelial
progenitor cells to differentiate into functional alveolar epithe-
lial cells despite the lactation failure (Figure 2c). SirT1 defi-
ciency may therefore alter the homeostasis of the signals for
ductal morphogenesis and/or the cellular response to the sig-
nals. Increased expression of both IGFBP-1 and IκBα in adi-
pose tissues and mammary epithelial cells could simply reflect
a global deregulation of gene expression in SirT1ko/ko cells in
which the activity of both FoxOs and NF-κB is increased.
IGFBP-1 is a potent inhibitor of IGF-1 in vivo [40], suggesting
that the elevated basal level of IGFBP-1 in adipose tissues in
SirT1ko/ko mice could reduce the effect of IGF-1. Moreover,
deregulated IGFBP-1 expression, but not deregulated IκBα
expression, was reversed in response to increased levels of
estrogen in the mammary fat pads after implantation (Figure
4b). The finding is relevant to the fact that the expression of
IGFBP-1 is downregulated as the level of estrogen increases
in pregnant wild-type mice (Figure 3b). Increased levels of
estrogen therefore stimulate the production of stromal cell-
derived local IGF-1, which overcomes the IGFBP-1 barrier in
SirT1ko/ko mice and, ultimately, reverses the increased levels of
IGFBP-1 in mammary tissues.
It was noted that increased levels of estrogen and local IGF-1
did not interfere with the expression of IκBα (Figure 4b). To
determine whether deregulated IκBα expression in SirT1ko/ko
cells can be reversed, we treated MEFs with TNFα and meas-
ured the kinetics of IκBα expression. Three independent lines
of SirT1ko/ko MEFs were used, which displayed varying basal
levels of increased IκBα expression. Following IκBα degrada-
tion induced by TNFα, the levels of newly synthesized IκBα in
all three SirT1ko/ko MEFs were always higher than that of wild-
Figure 4
Estrogen implantation stimulates ductal elongation and site branchingn implantation stimulates ductal elongation and site 
branching. (a) Whole mount analysis of the mammary tissues from the 
virgin wild-type (+/+) and SirT1ko/ko mice implanted with estrogen pel-
lets (+E2) on day 14 and day 21. Scale bars = 200 μm. (b) Western 
blot analysis of the expression of insulin-like growth factor-1 binding 
protein-1 (IGFBP-1) and IκBα, with actin as a loading control, in mam-
mary tissues from the virgin wild-type (+/+) and SirT1ko/ko mice 
implanted with estrogen pellets on day 21.Page 7 of 12
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deficiency affects NF-κB signaling when the IκB kinase activa-
tion is normal.
Our current system might not be suitable for studying the
effects of SirT1 deficiency on NF-κB activation in vivo. NF-κB
signaling exhibits distinct biological responses because the
expression of IκBα depends on NF-κB activation while the
other isoforms of IκB (β and ε) are independent of NF-κB feed-
back [41]. For example, TNFα stimulation induces dampened
oscillatory behavior after the first hour, whereas lipopolysach-
aride treatment leads to stable NF-κB activation [42,43]. The
NF-κB signaling in the developing mammary gland is under the
temporal control of RANK signaling and IKKα activation [37].
The finding of increased levels of newly synthesized IκBα
within the first hour indicated that SirT1 deficiency could dis-
rupt the temporal control of NF-κB signaling to all types of
stimulation (Figure 6). It remains unknown, however, whether
the reduced IGF-1 signaling would affect the efficacy of RANK
signaling and IKKα activation in developing mammary glands.
The fact that individual SirT1ko/ko mice manifested varying
degrees of ductal morphogenesis (Figure 3a) makes it difficult
to dissect the potential compound effect of SirT1 deficiency
on both upstream IKKα activation and downstream NF-κB sig-
naling. Other experimental systems, such as mammary
epithelial cell-specific SirT1ko/ko female mice, may be used to
address this issue.
Discussion
Our study of SirT1ko/ko mice has unveiled a regulatory mecha-
nism by which SirT1 modulates the efficacy of estrogen-stim-
ulated local IGF-1 signaling for ductal morphogenesis. SirT1
Figure 5
Mammary epithelial cell proliferation and apoptosis in SirT1ko/ko mice on lactation day 1ary epithelial cell proliferatio  and ap ptosis in SirT1ko/ko mice on lactation day 1. (a) Upper panel: bromodeoxyurdine (BrdU) staining 
of the mammary sections from SirT1ko/ko (ko/ko) and wild-type (+/+) mice on day 13 of pregnancy (P13) and lactation day 1 (L1). From left to right, 
three terminal end buds (TEBs) at a scale of 100 μm, a single TEB, ducts, and alveolus of SirT1ko/ko mice at a scale of 20 μm, and ducts and alveolus 
of wild-type mice on P13 and L1 at a scale of 20 μm. Lower panel: TUNEL (Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labe-
ling) assay for apoptotic cells using sections neighbored to the sections for BrdU staining. (b) The quantitative analysis of BrdU-positive epithelial 
cells in TEBs, ducts, and alveoli of SirT1ko/ko mice on L1 (open bar) and wild-type mice on P13 (grey bar) and L1 (solid bar). (c) The quantitative anal-
ysis of TUNEL-positive cells in neighboring sections.Page 8 of 12
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attenuates the efficacy of IGF-1 signaling. As a result, SirT1ko/
ko mice manifest partial perinatal lethality and lactation failure
phenotypes, implicating the role of evolutionarily conserved
SirT1 in both postnatal survival and offspring survival of
mammals.
SirT1 balances the homeostasis of IGF-1 and IGFBP-1 in 
vivo
SirT1 is an integral part of the IIS system that checks and bal-
ances the efficacy of insulin and IGF-1 signals. The IGF-1 sig-
naling of the IIS system is required for survival after birth. As
illustrated in Figure 7a, the function of SirT1 parallels the linear
IGF-1/IGF-1 receptor/phosphoinositide-3'-OH kinase/Akt sig-
naling pathway, both of which can negatively regulate the tran-
scription activity of FoxOs. Mice harboring targeted mutations
in either IGF-1 or the IGF-1 receptor gene exhibit perinatal
lethality and growth retardation [44,45]. In the IGF-1 receptor-
expressing cells, the binding of insulin and/or IGF-1 activates
the phosphoinositide-3'-OH kinase and Akt kinase cascade
for survival [8,9,13]. The phosphoinositide-3'-OH kinase/Akt
signaling pathway is also highly conserved from worms to
mammals, and functions to modulate energy metabolism and
lifespan in lower organisms. The mammalian Akt kinase family
has three members, Akt1–Akt3, which provide specificity and
versatility. Mice lacking both the Akt1 and Akt2 genes display
perinatal lethal and growth retardation phenotypes that are
strikingly similar to that of either IGF-1 or IGF-1 receptor-defi-
cient mice [46]. In this regard, SirT1ko/ko mice, as well as other
strains of SirT1-deficienct mice, also exhibit perinatal lethal
and growth retardation phenotypes (Figure 1c and Table 1)
[22,23]. The consistent observation of perinatal lethal and
growth retardation phenotypes from our study and studies
with mice lacking IGF-1, the IGF-1 receptor, or Akt1/Akt2 sug-
gests that upregulated FoxO activity unleashes the expression
of downstream effector genes that lead to the birth-related
stress. This birth-related stress may be related to the switch
from a maternal level of IGF-1 to a neonatal level of IGF-1
because the surviving SirT1ko/ko mice can live into adulthood
and can reproduce despite the growth retardation phenotype
(Figure 1c). In this context, at least one of the FoxO-deficient
mice strains, FoxO3 (Foxo3a/FKHRL1)-deficient mice, grow
normally and develop functional mammary glands [47].
IGFBP-1 is one of six IGF-1 binding proteins, but is the only
one that can be negatively regulated by insulin [48]. IGF-1
binding proteins inhibit the action of local IGF-1 in a spatial
and temporal manner [40,49]. In mammalian cells, FoxO3 can
directly bind to the promoter of the IGFBP-1 gene and activate
Figure 6
SirT1 deficiency derails NF-κB signaling in response to TNFα stimulationficiency derails NF-κB signaling in response to TNFα stim-
ulation. (a) Western blot analysis of IκBα expression in SirT1ko/ko (ko/
ko) and wild-type (+/+) murine embryonic fibroblasts (MEFs) within the 
first hour after TNFα stimulation. Actin is used as a loading control. (b) 
The relative levels of newly synthesized IκBα in three independent 
SirT1ko/ko MEF lines (red circles, blue and green triangles) and wild-type 
MEFs after TNFα stimulation. For each line of MEFs, the unit of IκBα 
protein at each time point is relative to the unit 0 minutes after normali-
zation with actin.
Figure 7
SirT1 modulates estrogen–insulin-like growth factor-1 signaling for ductal morphogenesis: a modeldulates trogen–insulin-like growth factor-1 signaling 
for ductal morphogenesis: a model. (a) The insulin/insulin-like 
growth factor-1 (IGF-1) signaling system: both SirT1 and Akt kinases 
can negatively regulate the transcription activity of forkhead box 'other' 
protein (FoxO) proteins. SirT1 deficiency deregulates the expression of 
insulin-like growth factor-1 binding protein-1 (IGFBP-1), which may 
exert autocrine and/or paracrine effects to inhibit IGF-1. (b) Mammary 
epithelial precursor cells (EPC) express IGF-1 receptor (IGF-1R) and 
can differentiate into estrogen receptor (ER)-negative ductal epithelial 
cells (DEC-I) in response to maternal, circulating, or estrogen-stimu-
lated, stromal cell (S)-derived local IGF-1. At the onset of puberty, ovar-
ian estrogen, in synergy with growth hormone (GH), enhances the 
production of local IGF-1 and stimulates the differentiation of DEC-I to 
ER-positive ductal epithelial cells (DEC-II). SirT1 deficiency deregu-
lates the expression of IGFBP-1 in adipose tissues (a), however, which 
attenuates the efficacy of the IGF-1 signaling and causes impeded duc-
tal morphogenesis in virgin SirT1ko/ko mice. Either pregnancy or exoge-
nous estrogen can overcome the impeded ductal morphogenesis in 
virgin SirT1ko/ko mice and can stimulate the differentiation of EPC.Page 9 of 12
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activity of nuclear FoxO3 and to decrease the expression of
IGFBP-1 when the IGF-1 signal is low (Figure 7a). Increased
levels of IGFBP-1 can diminish the action of IGF-1 signals in
vivo. In that way, SirT1 balances the homeostasis of IGF-1 and
IGFBP-1 for varying levels of IGF-1 signals.
The homeostasis of IGF-1 and IGFBP-1 clearly affects fertility,
as shown by the infertility phenotype in both IGF-1-deficient
mice and IGFBP-1 transgenic mice [28,40,49]. The serum
level of estrogen in IGF-1-deficient female mice appears sig-
nificantly reduced, whereas in ERα-deficient mice, which are
also infertile, there is a threefold increase [53]. In contrast,
SirT1ko/ko mice can be fertile despite the fact that the fertility
was reduced as compared with that of wild-type females
(Table 1). Although our preliminary assessment indicated that
the serum level of estrogen in SirT1ko/ko female mice was not
overtly altered, it remains possible that a subtle irregularity or
an individual variation of the estrogen level or ERα expression
might be attributed to the reduced fertility. An alternative
explanation for reduced fertility is that SirT1 deficiency dereg-
ulates the activity of FoxO3 and manifests an opposite effect
of FoxO3 deficiency. FoxO3-deficient mice exhibit early deple-
tion of ovarian follicles, which is reminiscent of premature ovar-
ian failure in women [47,54]. Premature ovarian failure
manifests as early cessation of ovarian function and as prema-
ture menopause caused by genetic mutations, chemo/radia-
tion therapy, or other unknown factors. It is possible that SirT1
deficiency counterbalances normal release of ovarian follicles
and reduces the fertility in mice.
SirT1 modulates the efficacy of the IGF-1 signal for 
ductal morphogenesis
We hypothesize that, in virgin SirT1ko/ko mice, increased levels
of IGFBP-1 in adipose tissues effectively diminish IGF-1
signals, including the estrogen–IGF-1 signaling, and halt the
differentiation of mammary epithelial progenitor cells (Figure
7b). Several results of this study provided support for this
hypothesis. First, the expression of IGFBP-1 is increased in
mammary fat pads from virgin SirT1ko/ko mice, in which there is
no evidence of any duct (Figures 2a and 3a). Second, both
pregnancy and estrogen implantation can rescue impeded
ductal morphogenesis in SirT1ko/ko mice (Figures 3a and 4a),
demonstrating that increased levels of estrogen can enhance
the production of local IGF-1. Moreover, the varying degrees
of rescue among individual mice, as well as individual mam-
mary fat pads of the same mouse, also indicated that local IGF-
1 must be halted in SirT1ko/ko mice (Figure 3a, and data not
shown). Finally, increased levels of estrogen specifically acti-
vate the IGF-1 signaling in mammary tissues, as shown by the
reversal of IGFBP-1 expression in SirT1ko/ko mice after estro-
gen implantation (Figure 4b). These results indicate that a gra-
dient of IGF-1 signals, including both circulating and local IGF-
1, may regulate mammary gland development at embryonic,
postnatal, and reproductive stages, and that increased expres-
sion of IGFBP-1 decreases the efficacy of IGF-1 signals.
Mammary development may undergo estrogen/IGF-1-inde-
pendent phases and estrogen/IGF-1-dependent phases,
which encompasses a late stage of embryonic development to
the onset of puberty and involves maternal IGF-1, circulating
IGF-1, and estrogen-stimulated local IGF-1. By embryonic day
16.5, mammary mesenchymes are connected to primitive fat
pads and begin to proliferate, which results in rudimentary
ducts [17,25,55,56]. We propose that this process marks the
transition from estrogen/IGF-1-independent mammary stem
cells to IGF-1-dependent epithelial progenitor cells, and that
maternal IGF-1 is sufficient to stimulate the differentiation of
epithelial progenitor cells to estrogen-independent ductal epi-
thelial cells but not estrogen-dependent epithelial cells (Figure
7b). This explains why the development of rudimentary ducts
is normal in either IGF-1 or ERα knockout mice and that TEBs
form and regress immediately before and after birth, respec-
tively [17,26,27]. During the prepubertal period, the rudimen-
tary ducts grow isometrically under the influence of circulating
IGF-1. Like maternal IGF-1, circulating IGF-1 is not sufficient
to induce the differentiation of estrogen-independent ductal
epithelial cells into estrogen-dependent epithelial cells, which
will express ERα and become estrogen dependent (Figure
7b). At the onset of puberty, ovarian estrogen, in synergy with
pituitary GH, causes a surge in the production of stromal cell-
derived local IGF-1 and stimulates the differentiation of estro-
gen-independent ductal epithelial cells to estrogen-dependent
epithelial cells, which begins postnatal development of mam-
mary gland (Figure 7b). Impeded ductal morphogenesis
results in virgin SirT1ko/ko mice because local IGF-1 is appar-
ently not sufficient to overcome increased IGFBP-1 in mam-
mary adipose tissues. SirT1 therefore positively regulates the
efficacy of the estrogen–IGF-1 signaling for ductal epithelial
cell proliferation and differentiation.
The potential effect of modulating SirT1 activity
Breast cancer results from the accumulation of inherited and/
or somatic mutations. Lifetime exposure to estrogen is a major
risk factor for breast cancer, and a number of lifestyle factors,
such as diet, body fat, alcohol consumption, exercise, parity,
and hormone replacement therapy, may influence a woman's
exposure to estrogen. The compound personal risk to a
woman is difficult to assess because the molecular link
between these factors and the effect of estrogen is poorly
understood. The result of this study demonstrated that SirT1
positively modulates the efficacy of the estrogen–IGF-1 signal.
This suggests that if SirT1 serves as a lifetime sensor to die-
tary restriction and acute withdrawal of nutrients [14,57], its
activity could ultimately influence the risk of breast cancer.
Interestingly, an epidemiological study of Dutch famine in
1945 indicated that an exposure to famine at prepubertal age
increased the risk of breast cancer, most clearly seen in
women who never gave birth [58]. Moreover, the serum levelsPage 10 of 12
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to the famine, which suggests that an epigenetic adaptation
phenomenon may take place. Assessing the potential correla-
tion between the enzymatic activity of SirT1 and the risk of
breast cancer is therefore of great interest in order to identify
feasible targets for chemoprevention against breast cancer.
Several dietary polyphenols as well as small molecules have
been identified as either agonists or antagonists of SirT1
[59,60]. The pharmacological effects of these compounds in
humans remain elusive given that SirT1 targets multiple tran-
scription factors and exerts pleiotropic effects. Nonetheless,
our study of SirT1ko/ko mice demonstrated the potential utility
of SirT1 antagonists. Specifically, reducing SirT1 activity alters
the homeostasis of cellular responses, including deregulation
of the expression of IGFBP-1 and IκBα, which can attenuate
the stimulation from the estrogen–IGF-1 signaling and poten-
tially desensitize mammary epithelial cells to NF-κB activation.
SirT1 is therefore a candidate target for chemoprevention
against breast cancer.
Conclusion
The study of mammary gland development is an excellent
model system for unraveling how SirT1 modulates the efficacy
of the estrogen–IGF-1 signaling and regulates the timing of
ductal morphogenesis. These new mechanistic insights may
also aid in understanding the role of SirT1 in breast cancer as
well as in other organs in which local IGF-1 plays an important
role.
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